The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer. READ MORE
Investigators assessed how response rate changed when patients were treated with different doses of brigatinib.
Investigators compared the safety and efficacy of docetaxel plus plinabulin with docetaxel alone in patients with NSCLC.
Using four key quality interventions in patients with non-small cell lung cancer who undergo surgery.
How does stereotactic body radiation therapy affected rates of non-cancer-related deaths?
The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer.
Long-term data from a recent trial suggest that continuation of treatment with first-generation EGFR TKIs beyond EGFR-positive NSCLC progression does not improve overall survival.
The American Society of Clinical Oncology has updated their guideline on systemic therapy for non-small cell lung cancer for the first time since 2015.
Research in Review
A new prognostic model provides personalized and disease-specific predictive information for patients with non-small cell lung cancer (NSCLC) and may result in better survival outcomes.
A second-generation inhibitor delays anaplastic lymphoma kinase-positive lung cancer growth for a median of 15 months longer and causes fewer adverse events than the current standard of care.
Few patients treated with immunotherapy for metastatic non–small cell lung cancer at US community practices receive appropriate programmed death-ligand 1 expression testing.
Patients with non-small cell lung cancer and synchronous brain metastasis demonstrate improved 1-year and 5-year overall survival after thoracic surgery and systemic chemotherapy.